NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
Chondrosarcoma has no proven systemic option in the metastatic setting. The development of a non-cross-resistant strategy, such as cellular immunotherapy using antigen-specific T cells would be highly desirable. NY-ESO-1 and PRAME are members of the Cancer Testis Antigen (CTA) family that have been...
Main Authors: | Seth M Pollack, Yonqing Li, Megan J Blaisdell, Erik A Farrar, Jeffrey Chou, Benjamin L Hoch, Elizabeth T Loggers, Eve Rodler, Janet F Eary, Ernest U Conrad, Robin L Jones, Cassian Yee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3288075?pdf=render |
Similar Items
-
Response to PD1 inhibition in conventional chondrosarcoma
by: Michael J. Wagner, et al.
Published: (2018-09-01) -
Immune-Based Therapies for Sarcoma
by: Seth M. Pollack, et al.
Published: (2011-01-01) -
Expression of PRAME gene in multiple myeloma
by: I В Abramenko, et al.
Published: (2004-07-01) -
10.5937/pramed1802081M
by: Uredništvo
Published: (2018-01-01) -
The expansion of the PRAME gene family in Eutheria.
by: Ti-Cheng Chang, et al.
Published: (2011-01-01)